Investor Alert: Glancy Prongay & Murray LLP Commences Investigation on Behalf of Carbylan Therapeutics, Inc. Investors

LOS ANGELES--(BUSINESS WIRE)--

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of investors of Carbylan Therapeutics, Inc. ("Carbylan" or the "Company") CBYL concerning the Company and its officers' possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.

Carbylan is a pharma firm that manufactures and commercializes innovative, chemically engineered polymer systems and proprietary combination therapies for such conditions as the treatment of pain associated with osteoarthritis of the knee.

On April 9, 2015, Carbylan held its Initial Public Offering, selling 13 million shares of its stock and generating $65 million in capital. On February 1, 2016, Carbylan announced its top-line results from its first Phase 3 trial of Hydros-TA for the treatment of knee pain connected with osteoarthritis. The Company announced that only one of two primary endpoints had been achieved in the Phase 3 trial.

On this news, Carbylan shares fell $1.81 per share, or over 73%, to close on February 2, 2016 at $0.66 per share.

If you purchased Carbylan securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by e-mail please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160324005335/en/